Toth Financial Advisory Corp Takes Position in Establishment Labs Holdings Inc. $ESTA

Toth Financial Advisory Corp acquired a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the second quarter, Holdings Channel.com reports. The fund acquired 7,400 shares of the company’s stock, valued at approximately $635,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ESTA. BlackRock Inc. purchased a new stake in Establishment Labs in the second quarter valued at about $135,752,000. William Blair Investment Management LLC purchased a new stake in shares of Establishment Labs during the second quarter worth about $61,273,000. Bank of America Corp DE purchased a new stake in shares of Establishment Labs during the second quarter worth about $52,176,000. Rice Hall James & Associates LLC acquired a new position in shares of Establishment Labs during the second quarter valued at about $48,134,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after acquiring an additional 438,206 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $70.64 on Friday. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -53.92 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The company has a 50 day moving average price of $85.00 and a 200-day moving average price of $74.91. Establishment Labs Holdings Inc. has a 1-year low of $36.53 and a 1-year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.57) EPS. Equities research analysts forecast that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on ESTA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Needham & Company LLC upped their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Mizuho lifted their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Finally, Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.